May 2, 2011 -- BeiGene, a Beijing startup that focuses on oncology drugs, announced an initial investment from Merck today. The exact size of the investment was not disclosed. But John Oyler, CEO of BeiGene and a Co-Founder, told ChinaBio® Today in an exclusive interview that the Merck commitment is “large.” Best of all, said Oyler, the agreement with Merck allows BeiGene to raise money from other pharmas and investors. That’s important, because BeiGene will need to be a champion fund raiser. More details....
Stock Symbol: (NYSE: MRK)
